- Full text PDF available (0)
- This year (0)
- Last five years (2)
UNLABELLED One of the few treatment options for inoperable neuroendocrine tumors (NET) is peptide receptor radiotherapy with somatostatin analogs. In this study, we compared the dosimetric parameter uptake, half-life (kinetics), and mean absorbed organ and tumor doses of (177)Lu DOTA-NOC and (177)Lu DOTA-TATE. METHODS Ninety-five (95) post-therapeutic… (More)
PURPOSE The aim of the study was to compare sequential (177)Lu-DOTA-TATE planar scans ((177)Lu-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic (68)Ga-DOTA-TATE positron emission tomography (PET)/CT ((68)Ga-DOTA-TATE) maximum… (More)
PURPOSE The objective of this study is to analyze the in vivo behavior of the (177)Lu-labeled peptides DOTATATE, DOTANOC, and DOTATOC used for peptide receptor radionuclide therapy (PRRNT) of neuroendocrine tumors (NETs), by measuring organ and tumor kinetics and by performing dosimetric calculations. METHODS Two hundred fifty-three patients (group 1)… (More)
30 eye-healthy subjects were being examined, with their pupils reacting, mydriatic or miotic. Their pattern reversal visual evoked cortical potentials (PRVECP's) were recorded under steady-state conditions. Test conditions allowed establishing a statistically significant influence of pupil size on the PRVECP.